Products with Anti-leishmanial bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2163 | Veraguensin |
| 1. Veraguensin shows activity against trypomastigote T. cruzi. 2. Veraguensin and galgravin can inhibit bone resorption and may offer novel compounds for the development of drugs to treat bone-destructive diseases such as osteoporosis. 3. Veraguensin shows high antileishmanial activity. | |
| BCN2568 | Mevastatin |
| Mevastatin inhibits HMGCR (HMG-CoA reductase) which in turn inhibits isoprenoid biosynthesis and therefore blocks protein isoprenylation and reduces plasma cholesterol levels in humans. Mevastatin inhibits the differentiation of TAO derived orbital preadipocytes by blocking PPAR-gamma mRNA expression. Mevastatin induces cell growth inhibition and apoptosis in SACC cells, it triggers the phosphorylation of the EGFR and inhibits the c-Jun N-terminal kinase pathway. | |
| BCN2661 | Amarogentin |
| 1. Amarogentin incorporated in liposomes or niosomes may have clinical application in the treatment of leishmaniasis. 2. Amarogentin plays cemopreventive/therapeutic role during liver carcinogenesis through modulation of cell cycle and apoptosis. 3. Amarogentin prevents platelet activation through the inhibition of PLC γ2-PKC cascade and MAPK pathway, it may offer therapeutic potential for preventing or treating thromboembolic disorders. | |
| BCN2729 | Primin |
| Primin has antimycobacterial, and strong antineoplastic actions. Primin has potent activity against Trypanosoma brucei rhodesiense (IC50 0.144 microM) and Leishmania donovani (IC50 0.711 microM), and low cytotoxicity (IC50 15.4 microM) on mammalian cells; it could serve as a lead compound for the rational design of more potent and less toxic antiprotozoal agents. | |
| BCN2763 | Valechlorine |
| 1. Valeranone shows antileishmanial and cytotoxic activity. | |
